Compare Globus Medical Inc. Class A Common Stock (GMED) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs XPO Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while XPO Inc. Common Stock trades at $187.74 (market cap $21.21B). The key difference: XPO Inc. Common Stock is far larger — about 2.1× Globus Medical Inc. Class A Common Stock's market cap, and XPO Inc. Common Stock is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and XPO Inc. Common Stock for 6 Days on average.
| GMED | XPO | |
|---|---|---|
Market Cap | $10.25B | $21.21B |
Volume | 1,108,124 | 663,957 |
Sector | Health | Industrials |
52-Week High | $96.82 | $228.37 |
52-Week Low | $58.33 | $123.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $24.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
XPO trades at $181.15, up 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.6B in 2026, and net income margin improved to 4.71%. Recent news highlights operational expansions and industry recognition, such as new service centers and a FreightTech 100 award.
The outlook is positive with strong analyst support—71.9% recommend Buy and a consensus price target of $227.64 implies ~26% upside. Key risks include high valuation multiples (P/E 53.44) and exposure to freight market volatility. Earnings growth and margin improvements are primary catalysts, but investors should monitor competitive pressures and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
